Camilla Svensson

Professor Svensson obtained her PhD at UC San Diego, where she also held a postdoctoral research position at the Department of Medicine. She subsequently moved on to Karolinska Institute, Stockholm, Sweden, where she today holds a position as Professor in Cellular and Molecular Pain Physiology and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology. Her research is focused on investigating the role of neuroinflammation in the peripheral and the central nervous system, with particular focus on pain mechanisms in conditions with joint inflammation and autoimmunity, such as rheumatoid arthritis. Professor Svensson brings vast disease area knowledge to the Advisory board and will be a key contributor in shaping Cellectricon’s chronic pain R&D strategy.

Henrik Zetterberg

Dr. Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and at University College London, UK, as well as the Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden. With a background in molecular biology and medicine, Dr. Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has published more than 900 scientific articles and has received the Erik K. Fernström prize for young scientists, the Inga Sandeborg prize for research on Alzheimer’s disease and the Parkinson Research Foundation Research Award. Professor Zetterberg brings extensive expertise in neurodegenerative diseases to the Advisory board, and he will be a key contributor in further enhancing Cellectricon’s CNS discovery services.

Thomas Nieland

Dr. Nieland obtained his PhD at the VU University of Amsterdam and currently holds the position of Research Associate Professor at the Biomedical Engineering Department of Tufts University in Boston, MA. He also shares leadership of the Initiative of Neural Science, Disease and Engineering at Tufts University (INSciDE@Tufts). This is an interdisciplinary research center with the mission to accelerate the discovery of therapeutic solutions to brain disease, integrating technological innovations in biomedical engineering with stem cell biology and regenerative medicine. Dr. Nieland brings extensive expertise in neurodegenerative disease, neuropsychiatry and stem cell research to the Advisory board, and he will be a key contributor in further enhancing Cellectricon’s CNS disease research. At Tufts University, Dr. Nieland’s research is focused on human brain disease, in particular on identifying disease mechanisms, targets and drugs to treat autism spectrum disorders, Parkinson’s and Alzheimer’s disease. Previously, Dr. Nieland performed research at Harvard University, MIT, the Broad Institute of Harvard and MIT, Johns Hopkins University, Stanford University and Merck Research Laboratories.

Franziska Denk

Dr. Denk studied Experimental Psychology at the University of Oxford and completed her DPhil there in 2009. She is currently a Lecturer at Wolfson Centre for Age-Related Diseases, King’s College London, where she and her research group work on neuroimmune interactions and epigenetic mechanisms in the context of chronic pain. Dr. Denk is passionate about data sharing and interdisciplinary research in an open, positive research culture. She is also looking to promote these values with future generations of scientists, as Co-Director of a recently established Wellcome Trust PhD Training Scheme in Neuro-immune Interactions at King’s College London. With her knowledge of neuroimmune interactions, Dr. Denk will be a key contributor to shaping Cellectricon’s new offering for chronic pain research.

Jonathan Levenson

Dr. Levenson is the Chief Scientific Officer at FireCyte Therapeutics and has over 16 years of experience as a neuroscientist in neuropsychiatry, neurodegeneration, and neuroinflammation. He has a Ph.D. in Biology from the University of Houston and did his postdoctoral training at the Baylor College of Medicine in the Department of Neuroscience. Prior to FireCyte, Dr. Levenson was Vice President of Translational Medicine at Tiaki Therapeutics, where he helped develop an integrated neuroinflammatory translational platform that more faithfully recapitulated disease processes occurring in patients. He was the head of preclinical and nonclinical research and development at Proclara Biosciences, where he was key in moving two assets that targeted and remodeled amyloid aggregates from early research into the clinic. He has held academic appointments at the University of Wisconsin-Madison and the Baylor College of Medicine. Dr. Levenson brings extensive expertise in neuroinflammatory and neurodegenerative diseases to the Advisory board, and he will be a key contributor in shaping Cellectricon’s services for neuroinflammatory research.